The Association of P2Y12 Inhibitor Pretreatment With Length of Stay Among Patients With Acute Coronary Syndrome Who Underwent Coronary Artery Bypass Graft Surgery: A Cohort Study

• DOI: 10.1155/cdr/8959128
• Publication Date: 2025-04-09T06:26:11Z
• Authors: Kramer J. Wahlberg; Cyrus Thomas-Walker; Bradley J. Tompkins; Juvena Hitt; Allen B. Repp; William Hopkins

Introduction: Recent clinical practice guidelines do not recommend routine P2Y12 inhibitor pretreatment for patients with non-ST-elevation acute coronary syndromes (NSTE-ACS) treated an early invasive strategy based upon trial data suggesting no improvement in outcomes and increased risk of bleeding. A subset NSTE-ACS who receive subsequently require artery bypass graft (CABG) surgery may lengthy washout to reduce periprocedural bleeding risk, potentially prolonging hospitalization increasing costs. We sought study the association on value-based including length stay, cost, discharge destination. Methods: conducted a retrospective cohort presenting underwent CABG at tertiary academic medical center between 2019 2021. assessed frequency over period compared risk-adjusted cost hospitalization, destination among did or pretreatment. Results: One hundred eighty-eight met inclusion criteria, 77% received The rate decreased significantly (p < 0.001). Pretreatment was associated longer preoperative stay (4.2 ± 1.6 vs. 3.4 2.5 days, p = 0.019), significant difference postoperative total stay. There likelihood home following CABG. Conclusion: Among inpatient CABG, but this observational, single-center study.